FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 38 of the 38 references it cites were found in a registry or an index; 22 of the 48 sources its claims cite were checked for support.
Abstract
Prostate cancer progression to the androgen-independent (AI) state involves acquisition of pathways that allow tumor growth under low-androgen conditions. We hypothesized that expression of molecular chaperones that modulate androgen binding to AR might be altered in prostate cancer and contribute to progression to the AI state. Here, we report that the Hsp90 cochaperone FKBP51 is upregulated in LAPC-4 AI tumors grown in castrated mice and describe a molecular mechanism by which FKBP51 regulates AR activity. Using recombinant proteins, we show that FKBP51 stimulates recruitment of the cochaperone p23 to the ATP-bound form of Hsp90, forming an FKBP51-Hsp90-p23 superchaperone complex. In cells, FKBP51 expression promotes superchaperone complex association with AR and increases the number of AR molecules that undergo androgen binding. FKBP51 stimulates androgen-dependent transcription and cell growth, and FKBP51 is part of a positive feedback loop that is regulated by AR and androgen. Finally, depleting FKBP51 levels by short hairpin RNA reduces the transcript levels of genes regulated by AR and androgen. Because the superchaperone complex plays a critical role in determining the ligand-binding competence and transcription function of AR, it provides an attractive target for inhibiting AR activity in prostate cancer cells.
Overview
CoChat Summary
TL;DR
FKBP51 is overexpressed in an androgen-independent LAPC-4 prostate cancer xenograft model and promotes assembly of an FKBP51-Hsp90-p23 superchaperone complex that increases the number of androgen-bound AR molecules. This provides a feed-forward mechanism for AR signaling and growth under low-androgen conditions, and suggests the superchaperone complex as a therapeutic target.
Key findings
- FKBP51 protein was elevated about threefold and FKBP51 mRNA 7- to 10-fold in LAPC-4 AI tumors grown in castrated mice versus AD tumors; S100P was upregulated 6- to 15-fold, and PSA was slightly higher in two of three AI xenografts.
- FKBP51 enhanced androgen-stimulated AR transcription from PSA, probasin, MMTV, and synthetic ARE reporters, while inhibiting dexamethasone-stimulated GR transcription; FK506 blocked FKBP51 enhancement of AR activity.
- FKBP51 promoted formation of an FKBP51-Hsp90-p23 ternary complex; assembly required ATP or AMP-PNP but not hydrolysis, was inhibited by geldanamycin and FK506, and required the AR ligand-binding domain for AR association.
- FKBP51 expression increased androgen-binding sites by 38% without changing AR levels or affinity, approximately doubled the PP2A/AR ratio in an androgen-bound AR assay, and FKBP51 knockdown reduced KLK2, PSA, and S100P transcripts; FKBP51 also gave a growth advantage at 50 pM R1881 (P < 0.001).
Methods
- LAPC-4 xenografts were grown in intact or castrated scid mice; prostate cancer cell lines PC-3 (AR-negative), LNCaP, and CWR22Rv1 (AR-positive) were used, with lentiviral FKBP51 overexpression or shRNA knockdown.
- AR activity was measured by dual-luciferase reporter assays and real-time PCR for endogenous AR-regulated genes; chaperone complexes were analyzed by immunoprecipitation/immunoblotting and by gel filtration with recombinant FKBP51, Hsp90, and p23.
- Androgen binding was measured by whole-cell [3H]R1881 binding and a PP2A-AR coimmunoprecipitation assay; growth was measured by MTT assay, with Student t tests and nonlinear regression for Bmax/Kd.
Limitations
- The paper states no explicit limitations section.
- Evident from the text: the mechanistic work relies heavily on overexpression in AR-negative PC-3 cells and recombinant proteins, and the in vivo evidence is limited to expression differences in LAPC-4/CWR22 xenografts rather than direct FKBP51 manipulation in tumors.
- The paper notes that FKBP51 overexpression was not detected in a previous microarray analysis of LAPC-4 xenografts, and that FKBP51 knockout mice lack overt androgen-signaling defects, leaving the normal physiological contribution of FKBP51 unclear.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
17 Valid · 3 Not valid · 21 Not checked · 88 Own results and interpretations
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Because the FKBP51 knockout mouse does not display overt defects in androgen signaling (4, 37), the contribution of FKBP51 to AR function has been unclear.”
What the sources say
- Could not verifycites [4] 4. Cheung-Flynn, J., V. Prapapanich, M. B. Cox, D. L. Riggs, C. Suarez-Quian, and D. F. Smith. 2005. Physiological role for the cochaperone FKBP52 in androgen receptor signaling. Mol. Endocrinol. 19: 1654-1666. sourceExperimental — accuracy not yet measured
The “52KO Mice” section describes an FKBP52 knockout with reproductive defects, not an FKBP51 knockout. Searches for FKBP51, Fkbp5, and 51KO found no passage in our copy addressing whether FKBP51-knockout mice have overt defects in androgen signaling. (LLM, conf=0.76)
- Not checked — no full text of the sourcecites [37] 37. Yong, W., Z. Yang, S. Periyasamy, H. Chen, S. Yucel, W. Li, L. Y. Lin, I. M. Wolf, M. J. Cohn, L. S. Baskin, E. R. Sanchez, and W. Shou. 2007. Essential role for cochaperone Fkbp52 but not Fkbp51 in androgen receptor-mediated signaling and physiology. J. Biol. Chem. 282: 5026-5036. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“Reintroduction of AR into PC-3 cells activates the endogenous FKBP51 gene, an observation that is consistent with AR regulation of FKBP51 expression (11).”
What the sources say
- Supportedcites [11] 11. Kesler, C. T., D. Gioeli, M. R. Conaway, M. J. Weber, and B. M. Paschal. 2007. Subcellular localization modulates activation function 1 domain phosphorylation in the androgen receptor. Mol. Endocrinol. 21: 2071-2084. source
The results passage on AR activity reports that AR was expressed in PC3 cells and that FKBP51 expression was activated when the cells were treated with R1881. The Fig. 5 caption also identifies FKBP51 mRNA induction after AR expression and R1881 addition; the experiment therefore supports the claim under androgen-treated conditions. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“FKBP51 negatively regulates GR and PR activity by reducing hormone binding affinity (6, 9).”
What the sources say
- Not checked — no full text of the sourcecites [6] 6. Denny, W. B., D. L. Valentine, P. D. Reynolds, D. F. Smith, and J. G. Scammell. 2000. Squirrel monkey immunophilin FKBP51 is a potent inhibitor of glucocorticoid receptor binding. Endocrinology 141: 4107-4113. source
- Partly supportedcites [9] 9. Hubler, T. R., W. B. Denny, D. L. Valentine, J. Cheung-Flynn, D. F. Smith, and J. G. Scammell. 2003. The FK506-binding immunophilin FKBP51 is transcriptionally regulated by progestin and attenuates progestin responsiveness. Endocrinology 144: 2380-2387. sourceExperimental — accuracy not yet measured
The introduction states that squirrel monkey FKBP51 lowers hormone-binding affinity in the GR complex. The overexpression results show reduced PR responsiveness in HepG2 cells, but do not establish that reduced PR hormone-binding affinity is the mechanism; the Discussion instead suggests an interaction with hsp90. Page numbers are unavailable in our copy. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“a quantitative coimmunoprecipitation assay developed in our laboratory (35) that discriminates between androgen-free and androgen-bound forms of AR”
What the sources say
- Supportedcites [35] 35. Yang, C.-S., H.-W. Xin, J. B. Kelley, A. Spencer, D. L. Brautigan, and B. M. Paschal. 2007. Ligand binding to the androgen receptor induces conformational changes that regulate phosphatase interactions. Mol. Cell. Biol. 27: 3390-3404. source
The Discussion states that the AR–PP2A co-IP assay tests whether AR adopts an androgen-bound conformation. It also reports that PP2A release accompanies AR’s return to the androgen-free conformation, supporting the assay’s ability to distinguish the two forms. Page numbers are unavailable in our copy. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Mutations in the TPR domain that disrupt binding to Hsp90, described originally by Chinkers and associates in PP5 (29), were also constructed (M2).”
What the sources say
- Supportedcites [29] 29. Russell, L. C., S. R. Whitt, M. S. Chen, and M. Chinkers. 1999. Identification of conserved residues required for the binding of a tetratricopeptide repeat domain to heat shock protein 90. J. Biol. Chem. 274: 20060-20063. source
The citation identifies the original PP5 mutations, not the citing authors’ FKBP51 M2 construct. The Results report that mutations in the PP5 TPR domain disrupted Hsp90 binding, matching the work the citing sentence attributes to this source. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
88 more claims · 1 with their cited sources checked
Create a free account to see all 129 claims and every source verdict.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 19
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the relative activities of the FKBP51-bound and FKBP52-bound androgen receptors differ from that observed for the glucocorticoid and progesterone receptors such that a positive-feedback expression process can arise under pathological conditions which appears to often substantially contribute to the metastatic phase of prostate cancer [10–12].”
From Differential conformational dynamics in the closely homologous FK506-binding domains of FKBP51 and FKBP52 (2014) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“studies have shown that the FK506 anti-proliferative effect is mediated by FKBP51, rather than FKBP52 [24, 25].”
From FKBP51 – a selective modulator of glucocorticoid and androgen sensitivity (2011) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In LNCaP cells, treatment with FK506 inhibited the ligand-induced activity of AR at both reporter and endogenous genes by a mechanism that appears to reduce the intrinsic hormone-binding function of the receptor [24, 25].”
From FKBP51 – a selective modulator of glucocorticoid and androgen sensitivity (2011) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“treatment of LNCaP prostate cancer cells with geldanamycin, or its derivative 17-AAG, reduced AR protein stability, hormone-binding function and transcriptional activity [24, 54].”
From FKBP51 – a selective modulator of glucocorticoid and androgen sensitivity (2011) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the two most recent findings demonstrate that FKBP51 is nearly essential for androgen-induced growth of two different prostate cancer cell lines [24, 25].”
From FKBP51 – a selective modulator of glucocorticoid and androgen sensitivity (2011) · cites this paper as [24]
Experimental — accuracy not yet measured
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ RESULTS
“Finally, the M1, M2, and M1/M2 mutant forms have reduced activity in the PP2A-AR interaction assay, which is a readout of the number of AR molecules that are bound with androgen (Fig. 8C).”
§ RESULTS
“(D) Analysis of mutant forms of FKBP51 by using the PP2A-AR to assess the effect on androgen binding to AR.”
Citations
Cites
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278 · cited 5×
“FKBP51 overexpression was not detected in a previous microarray analysis of the LAPC-4 xenografts (3).”
BackgroundMethodInfluentialSteroid Receptor Interactions with Heat Shock Protein and Immunophilin Chaperones*
Pratt, W. B., & Toft, D. O. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.3.0303 · Cited by 1,791
Self-citationStructure and mechanism of the Hsp90 molecular chaperone machinery
Pearl, L. H., & Prodromou, C. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142738 · Cited by 1,103
Crystal structure of an Hsp90–nucleotide–p23/Sba1 closed chaperone complex
Ali, M. M. U., Roe, S. M., Vaughan, C. K., Meyer, P., Panaretou, B., Piper, P. W., Prodromou, C., & Pearl, L. H. (2006) · Nature · doi:10.1038/nature04716 · Cited by 962 · cited 3×
“Crystallographic analysis revealed that p23 recognizes the ATP-bound, closed conformation of Hsp90; a major contact surface for p23 is formed by “lid” closure of Hsp90 (1).”
BackgroundSteroid Receptor Interactions with Heat Shock Protein and Immunophilin Chaperones
Pratt, W. B. (1997) · Endocrine Reviews · doi:10.1210/er.18.3.306 · Cited by 641
The Hsp90 molecular chaperone: an open and shut case for treatment
Pearl, L. H., Prodromou, C., & Workman, P. (2008) · Biochemical Journal · doi:10.1042/bj20071640 · Cited by 447
Disassembly of Transcriptional Regulatory Complexes by Molecular Chaperones
Freeman, B. C., & Yamamoto, K. R. (2002) · Science · doi:10.1126/science.1073051 · Cited by 400 · cited 1×
“function, including transcription complex disassembly (8).”
Klein, K. A., Reiter, R. E., Redula, J., Moradi, H., Zhu, X. L., Brothman, A. R., Lamb, D. J., Marcelli, M., Belldegrun, A., Witte, O. N., et al. (1997) · Nature Medicine · doi:10.1038/nm0497-402 · Cited by 399
The Hsp90‐binding peptidylprolyl isomerase FKBP52 potentiates glucocorticoid signaling in vivo
Riggs, D. L., Roberts, P. J., Chirillo, S. C., Cheung‐Flynn, J., Prapapanich, V., Ratajczak, T., Gaber, R., Picard, D., & Smith, D. F. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg108 · Cited by 353
Dual Targeting of HSC70 and HSP72 Inhibits HSP90 Function and Induces Tumor-Specific Apoptosis
Powers, M. V., Clarke, P. A., & Workman, P. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.08.002 · Cited by 307 · cited 1×
“Highdose 17-AAG, however, causes skeletal complications and increases Hsp70 levels, the latter of which may promote tumor resistance to therapy (23, 25).”
Background
Cited by
Items 101–155 of 155
The Emerging Role of TPR-Domain Immunophilins in the Mechanism of Action of Steroid Receptors
Mazaira, G. I., Lagadari, M., Erlejman, A. G., & Galigniana, M. D. (2014) · Nuclear Receptor Research · doi:10.11131/2014/101094 · Cited by 12
“Interestingly, FKBP51 binding to Hsp90 favors the recruitment of the cochaperone p23 and positively regulates AR signaling [148] and is associated with chemoresistance and radioresistance [147, 149].”
BackgroundVelez, M. V. L., Dijkstra, J. J., Heuschkel, M. A., Smit, F. P., van de Zande, G., Smeets, D., Sedelaar, J. P. M., Vermeulen, M., Verhaegh, G. W. C. T., & Schalken, J. A. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12957 · Cited by 12
Chen, Y., Liu, Z., Wang, Y., Zhuang, J., Peng, Y., Mo, X., Chen, J., Shi, Y., Yu, M., Cai, W., et al. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8450 · Cited by 10
“Moreover, the TPR domains can form a super complex with a steroid receptor (11); therefore, these domains play important roles in cellular processes.”
BackgroundGorjala, P., Goodman, O. B., Kittles, R. A., & Mitra, R. (2020) · Cancers · doi:10.3390/cancers12040989 · Cited by 11
“A recent study uncovered a mechanism in which FKBP5 is found 25 to form a complex with HSP90 and promote AR signaling in prostate cancer [32].”
BackgroundFK506-binding protein 5 promotes the progression of papillary thyroid carcinoma
Gao, Z., Yu, F., Jia, H., Ye, Z., & Yao, S. (2021) · Journal of International Medical Research · doi:10.1177/03000605211008325 · Cited by 13
“Ni et al.(24) reported that FKBP5 stimulated androgen-dependent transcription and cell proliferation in prostate cancer.”
BackgroundZhang, C., Cui, X., Feng, L., Han, Z., Peng, D., Fu, W., & Xing, Y. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-21-71 · Cited by 10
“In recent years, FKBP-5 has also been found to have significant effects in the development of tumors (19-22).”
BackgroundDong, J., Jiao, Y., Mu, W., Lu, B., Wei, M., Sun, L., Hu, S., Cui, B., Liu, X., Chen, Z., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18903 · Cited by 11
IL-17RA/CTSK axis mediates H. pylori-induced castration-resistant prostate cancer growth
Lin, G.-W., Tian, F., Yu, Q., Weng, X., Yu, N., Zhang, F., Yi, C., Ye, J., & Ye, D. (2024) · Oncogene · doi:10.1038/s41388-024-03169-z · Cited by 10
“Additionally, several molecules act as co-activators and co-repressors of AR, regulating the transcriptional activity and growth stimulated by androgens, including the FKBP51/P23/ HSP90 molecular axis [18], the MAPK/SRC-1/IL-6 molecular axis [19], and the STAT3/P300/CBP/IL-6 molecular axis [20].”
Zhang, J., Wu, D., He, Y., Li, L., Liu, S., Lu, J., Gui, H., Wang, Y., Tao, Y., Wang, H., et al. (2020) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2020.100778 · Cited by 11
Surkin, P. N., Brenhouse, H. C., Deak, T., Liberman, A. C., & Lasaga, M. (2018) · Journal of Neuroendocrinology · doi:10.1111/jne.12602 · Cited by 8
“Since over-expression of FKBP51 is associated with deregulated GR activity and pathological adrenal responses [63], the inhibition of FKBP51 SUMO conjugation could be an interesting approach to modulate deregulated inflammatory and stress-related responses [69].”
BackgroundYaşar, Ş., & Melekoğlu, R. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1562558 · Cited by 10
Management of Patients with Castration-Resistant Disease
Pezaro, C. J., Omlin, A. G., Lorente, D., & Bono, J. S. D. (2013) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.08.008 · Cited by 7
“HSPs are chaperones that regulate binding of ligands to the AR and several other proteins involved in mitogenic signaling, and may be therapeutic targets.(65) Phase II clinical trials with HSP90 inhibitors alone (NCT01270880) or in combination with abiraterone (NCT01685268) are currently recruiting patients.”
BackgroundGao, Y., Elamin, E., Zhou, R., Yan, H., Liu, S., Hu, S., Dong, J., Wei, M., Sun, L., & Zhao, Y. (2018) · Oncology Letters · doi:10.3892/ol.2018.9517 · Cited by 8
“It is notable that FKBP51 is associated with the development of a variety of hormone-associated tumors, and previous studies have demonstrated that FKBP51 is overexpressed in androgen-dependent prostate cancer (8,10), and decreased Table I. FKBP51 expression in different patients and tissues.”
Bernadotte, A., Kumar, R., Winblad, B. G., & Pavlov, P. F. (2018) · FEBS Open Bio · doi:10.1002/2211-5463.12521 · Cited by 7
Barge, S., Jade, D., Ayyamperumal, S., Manna, P., Borah, J. C., Nanjan, C. M. J., Nanjan, M. J., & Talukdar, N. C. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1994877 · Cited by 8
Molecular determinants ofDrosophilaimmunophilin FKBP39 nuclear localization
Orłowski, M., Popławska, K., Pieprzyk, J., Szczygieł-Sommer, A., Więch, A., Zarębski, M., Tarczewska, A., Dobrucki, J. W., & Ożyhar, A. (2018) · Biological Chemistry · doi:10.1515/hsz-2017-0251 · Cited by 6
“It has also been shown that FKBP51 promotes androgen receptor (AR) activity in prostate cancer by facilitating the assembly of the Hsp90 chaperone complex (Ni et al., 2010) and that FKBP52 regulates AR transactivation activity in the nucleus (Chen et al., 2010).”
Background郭丹红, Peng, Y., & Yu, Y. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1755668 · Cited by 5
Charoensuksira, S., Meephansan, J., Vanichvongvan, R., Somparn, P., Tangtanatakul, P., Wongpiyabovorn, J., & Suchonwanit, P. (2024) · Archives of Dermatological Research · doi:10.1007/s00403-024-03453-8 · Cited by 6
Park, H., Park, J., Kim, T., Heo, H., Chang, J., Blackstone, C. D., & Lee, S. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04897-3 · Cited by 6
ADP-ribosylating toxins modifying the actin cytoskeleton
Barth, H., Stiles, B. G., & Popoff, M. R. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800188-2.00014-8 · Cited by 5
FKBP5 associated CD8 T cell infiltration is a novel prognostic biomarker in luminal B breast cancer
Tong, F., Lu, G., Zang, J., Hao, D., Xu, W., Chen, J., Ding, Q., & Xiong, H. (2023) · Journal of International Medical Research · doi:10.1177/03000605231211771 · Cited by 8
“39 Because of the lack of a more systematic study between FKBP5 and breast cancer, this current study was conducted to assess the clinical role and molecular regulatory importance of FKBP5 in LBBC.”
BackgroundAlteration of Ubiquitination in the Brain of ENOPH1 Knockout Mice after Early Ischemic Stroke
Wu, Y., Tang, P., Huang, Z., Gu, D., Yan, D., Su, L., & Zhang, Y. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.4c00913 · Cited by 4
Ma, J., Yang, Z., Gao, H., Huda, N., Jiang, Y., & Liangpunsakul, S. (2023) · Journal of Investigative Medicine · doi:10.1177/10815589231207793 · Cited by 4
“39,40 FKBP5 can also bind and alter the phosphorylation state of its target proteins.”
BackgroundNuclear Receptors: Mechanistic Insights into Endocrine Resistance in Prostate and Breast Cancers
Silva-Cázares, M. B., Núñez-Olvera, S. I., Hernández-Barrientos, R., et al. (2024) · Receptors · doi:10.3390/receptors3040022 · Cited by 4
Wang, X., Yin, D., Sun, J., Zhang, L., Ye, Y., & Guo, Q. (2025) · Inflammation · doi:10.1007/s10753-025-02321-5 · Cited by 5
“Literature has reported that Heat Shock Protein 90 (HSP90) binds to AR to stabilize its structure, and FKBP5 further influences AR function by regulating HSP90 activity [48].”
Role of the Hsp90-Immunophilin Heterocomplex in Cancer Biology
Leo, S. A. D., Zgajnar, N. R., Mazaira, G. I., Erlejman, A. G., & Galigniana, M. D. (2019) · Current Cancer Therapy Reviews · doi:10.2174/1573394715666190102120801 · Cited by 4
Li, A., Bao, J., Gao, S., He, Y., Nie, X., Hosyanto, F. F., He, X., Li, T., & Xu, L. (2023) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.3c00211 · Cited by 3
Functions of the Hsp90-Binding FKBP Immunophilins
Ortiz, N. R., Guy, N. C., Garcia, Y. A., Sivils, J. C., Galigniana, M. D., & Cox, M. B. (2022) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-14740-1_2 · Cited by 3
Hsa_circ_0003356 suppresses gastric cancer progression via miR-556-5p/FKBP5 axis
Lu, C., Wu, J., Li, X., Huang, W., Fang, Y., & Huang, Y. (2024) · Toxicology in Vitro · doi:10.1016/j.tiv.2024.105787 · Cited by 3
Velayo, C. L., Ito, T., Dong, Y., Endo, M., Sugibayashi, R., Funamoto, K., Iida, K., Yaegashi, N., & Kimura, Y. (2014) · ISRN Obstetrics and Gynecology · doi:10.1155/2014/193816 · Cited by 3
“Furthermore, expression patterns of targeted genes related to stress signaling pathways revealed decreased GR activity: Mapk8 (mitogen activated protein kinase 8) and Fkbp5 (FK506 binding protein 5), bothGR inhibitors [26, 27], were increased in the -D/S and -S groups; Mkp1 (mitogen activated protein kinase phosphatas…”
BackgroundHan, J., Zhu, Y., Pan, D., Xue, H., Wang, S., Peng, Y., Liu, H., He, Y., & Yao, X. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.07.015 · Cited by 4
D’Arrigo, P., Tufano, M., Rea, A., Romano, S., & Romano, M. F. (2016) · Springer eBooks · doi:10.1007/978-1-4614-6438-9_101769-1 · Cited by 3
Comprehensive androgen-dependent transcriptome analysis in human genital tissue
Sivaprasad, R., Händler, K., Caliebe, A., Spielmann, M., Holterhus, P., & Hornig, N. (2025) · BMC Genomics · doi:10.1186/s12864-025-12212-6 · Cited by 2
FKBP5 (FK506 binding protein 5)
Ellsworth, K., & Wang, L. (2014) · Atlas of Genetics and Cytogenetics in Oncology and Haematology · doi:10.4267/2042/53641 · Cited by 1
“Also, it influences steroid receptor signaling (Denny et al., 2000; Barent et al., 1998; Ni et al., 2010), NFκB pathway (Bouwmeester et al.”
BackgroundInfluentialMOLECULAR ASPECTS OF THE BONE METASTASTASES DEVELOPMENT IN PROSTATE CANCER
Piddubnyi, A. (2019) · Eastern Ukrainian Medical Journal · doi:10.21272/eumj.2019;7(2):96-108 · Cited by 2
HDAC6 Regulation of Androgen Signaling in Prostate Cancer
Ai, J., & Wang, Z. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6828-8_16 · Cited by 1
Linking the immunophilin FKBP5 to taxol resistance in ovarian cancer
(2015) · Cancer Cell & Microenvironment · doi:10.14800/ccm.692 · Cited by 1
Functional Protein Interactions in Steroid Receptor-Chaperone Complexes
Ratajczak, T., Rudi, K., Cluning, C., & Bryan, K. R. (2012) · InTech eBooks · doi:10.5772/38339 · Cited by 1
“The ability of FKBP51 to enhance AR transcription and chaperone complex assembly appears to be dependent on FKBP51 PPIase activity mediated by the FK1 domain and requires Hsp90 binding through its TPR domain (Ni et al. , 2010).”
BackgroundAlaee, S. (2014) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2014.329 · Cited by 2
“Studies on male reproductive system confirmed the role of these co-chaperones in reproductive system development, in cancers and also in fertility disorders related to androgen receptor function (13, 18-22).”
BackgroundKumar, R., Winblad, B. G., & Pavlov, P. F. (2019) · Heat shock proteins · doi:10.1007/978-3-030-23158-3_14 · Cited by 1
Androprostamine A: a unique antiprostate cancer agent
Yamazaki, Y. M., Abe, H., Sakashita, C., Ohba, S., Watanabe, T., Momose, I., & Kawada, M. (2021) · The Journal of Antibiotics · doi:10.1038/s41429-021-00449-8 · Cited by 1
Role of Peptidyl-Prolyl cis/trans Isomerases in Cellular Uptake of Bacterial Protein Toxins
Barth, H. (2013) · Heat shock proteins · doi:10.1007/978-94-007-6787-4_16 · Cited by 1
Sex Hormone-Binding Globulin as a Modulator of the Prostate “Androgenome”
Scott, M., Nicholas, A., & Rosner, W. (2012) · InTech eBooks · doi:10.5772/38981
“…finding, as FKBP5 has been shown to be a limiting component of the HSP90 chaperone supercomplex that maintains the AR in its ligand binding state (Ni et al, 2010). www.intechopen.com Sex Steroids 42 These results support the view that endogenously expressed SHBG plays a significant role in…”
BackgroundNew Therapies in Hormone Relapsed Disease
Pezaro, C. J., Omlin, A. G., Bianchini, D., & Bono, J. S. D. (2014) · Prostate Cancer · doi:10.1002/9781118347379.ch14
Tavakoli, I. (2013) · cIRcle (University of British Columbia) · doi:10.14288/1.0072850 · Cited by 2
“Unbound AR is mainly located in the cytoplasm and associated with chaperone heat shock proteins, hsp 90, 70 and 56 and immunophillin proteins [65, 66].”
BackgroundHSP90-Based Heterocomplex as Essential Regulator for Cancer Disease
Galigniana, M. D. (2019) · Heat shock proteins · doi:10.1007/978-3-030-23158-3_2
Atlas of Genetics and Cytogenetics in Oncology and Haematology
Ellsworth, K. A., & Wang, L. (2014)
Shi, H., Zhong, F., Yi, X., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.730141
“Many members of the PPIases gene family have recently been found to be closely associated with cancer progression and prognosis (Hojo et al., 1999; Bao et al., 2004; Ni et al., 2010; Annett et al., 2020).”
BackgroundChaperones and ADP-Ribosylating Bacterial Toxins
Barth, H., & Ernst, K. (2018) · Toxinology · doi:10.1007/978-94-007-6449-1_7
D’Arrigo, P., Tufano, M., Rea, A., Romano, S., & Romano, M. F. (2017) · Springer eBooks · doi:10.1007/978-3-319-67199-4_101769
Genome-wide analyses of signaling pathways controlled by steroid receptors
Rerra, A. (2019) · theses.fr (ABES) · doi:10.70675/d10332bfzd22cz480cz8f5czc0114d6c93c5
Biomarqueurs circulants dans le cancer de la prostate métastatique résistant à la castration
Maillet, D. (2022) · theses.fr (ABES) · doi:10.70675/c764fae7z7ddcz4e95z96bez5039c3575f58
Bae, J., Han, G. H., Yun, H., Chung, J., Kim, J., & Cho, H. (2026) · Research Square · doi:10.21203/rs.3.rs-9525299/v1
Androgen Receptor and Steroidogenesis Pathway Control
Romano, S., Bisogni, R., & Romano, M. F. (2013) · Springer eBooks · doi:10.1007/978-94-007-7149-9_4
Metadata
- Authors
- Ni, L., Yang, C.-S., Gioeli, D., Frierson, H., Toft, D. O., & Paschal, B. M.
- Affiliations
- Center for Cell Signaling
- Departments of Microbiology
- University of Virginia (US)
- Mayo Clinic (US)
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2010-03
- Volume
- 30
- Issue
- 5
- Pages
- 1243-1253
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- PMC
- PMC2820886
- OpenAlex
- W2059122555
- Cited by
- 155
- References
- 37
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 6 · 2023: 8 · 2022: 10 · 2021: 11 · 2020: 4 · 2019: 8 · 2018: 9 · 2017: 7 · 2016: 10 · 2015: 16 · 2014: 15 · 2013: 14 · 2012: 9
- FWCI
- 11.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Molecular and Cellular Biology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense
- National Cancer Institute (P01CA104106, R01CA124706)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- FKBP51, HSP90, p23, androgen receptor, castration-resistant prostate cancer, androgen receptor signaling, androgen binding, positive feedback loop, molecular chaperones, prostate cancer progression, LAPC4 cells
- MeSH terms
- Prostaglandin-E Synthases, Tacrolimus Binding Protein 5, Animals, Base Sequence, Humans, Male, Models, Biological, Neoplasm Transplantation, Neoplasms, Hormone-Dependent, Prostatic Neoplasms, Receptors, Androgen, Recombinant Proteins, Transplantation, Heterologous, Signal Transduction, Up-Regulation, Mice, SCID, DNA Primers, HSP90 Heat-Shock Proteins, Intramolecular Oxidoreductases, Tacrolimus Binding Proteins, Cell Line, Tumor, Multiprotein Complexes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.